BEIGENE LTD-ADR (BGNE) Stock News

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio?

Large-cap stocks saw worst performance last week, including MongoDB, Applovin, CAVA, Super Micro Computer, FTAI, Adobe, Ferguson, Toll Brothers, BeiGene, Omnicom, and Nucor.

Mentions: APP ADBE SMCI IPG ...

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

BeiGene to Present at Upcoming Investor Conferences

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

/PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and...

Mentions: LH

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

China-Origin Drugmaker BeiGene to Rename Itself Amid Global Push

China’s leading innovative cancer drugmaker BeiGene Ltd. plans to change its name to BeOne Medicines as part of a rebranding to support its growth ambitions in markets including the US and Europe.

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

BeiGene to Present at the Jefferies London Healthcare Conference

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene Mourns Death of Beloved Board Member Donald Glazer

China Detains Ex-AstraZeneca Executive in Sign of Widening Probe

Chinese authorities are probing a former senior executive of AstraZeneca Plc in the country, local media outlets reported on Friday, in a sign Beijing is widening its scrutiny of the British pharmaceutical giant’s operations in mainland China.

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

/PRNewswire/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers...

Mentions: ONCY ABBV HCM ELVN

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

BeiGene Announces Updates to Commercial Leadership Team

BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference